Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.
Wout DevliesMarkus EcksteinAlessia CimadamoreGaëtan DevosLisa MorisThomas Van den BroeckRodolfo MontironiSteven JoniauFrank ClaessensThomas GevaertPublished in: Cells (2020)
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
Keyphrases
- end stage renal disease
- dna repair
- pi k akt
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- signaling pathway
- peritoneal dialysis
- prognostic factors
- primary care
- clinical trial
- randomized controlled trial
- machine learning
- patient reported outcomes
- patient reported
- deep learning
- phase ii
- clinical practice
- dna damage response
- artificial intelligence